Pharmacally
Gene therapy
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Gene therapy
Clinical TrialsOpus Genetics Reports Visual Function Gains with OPGx-BEST1 in Phase 1/2 BEST1 Gene Therapy TrialOpus Genetics reports visual and retinal improvements with OPGx-BEST1 in Phase 1/2 BIRD-1, supporting pivotal development in BEST1-related retinal disease.Fact-Checked
Clinical TrialsNG101 Gene Therapy Reduced Anti-VEGF Injection Frequency by 90% in Mid-Dose Cohort at 44 WeeksPhase 1/2a data presented at ASRS 2026 showed that NG101 gene therapy reduced supplemental anti-VEGF injection frequency by 90% through 44 weeks in the mid-dose cohort of patients…Fact-Checked
Mergers & AcquisitionsAstellas Taps Dyno’s AI-Designed AAV Capsid to Tackle Muscle Gene Therapy Dosing ChallengeAstellas Pharma has exercised its option to license an AI-engineered AAV capsid from Dyno Therapeutics for skeletal muscle gene therapy.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.